Financial Outlook for 2025 - Revenue is projected to be between $2.76 billion and $2.82 billion[7] - Adjusted EBITDA is expected to range from $376 million to $382 million[7] - Adjusted Net Income is forecasted to be between $81 million and $85 million[7] - Adjusted EPS is anticipated to be in the range of $1.02 to $1.07[7] Key Financial Metrics - Interest Expense is estimated to be $97 million to $100 million[7] - Gross Capital Expenditures are projected to be $205 million to $215 million[7] - Net Capital Expenditures are expected to be $135 million to $145 million[7] - The Adjusted Effective Tax Rate is projected to be between 29.5% and 30.5%[7] - Diluted Weighted Average Shares Outstanding are estimated to be approximately 80 million[7] Important Considerations - The company's outlook includes forward-looking statements subject to risks and uncertainties, as detailed in their SEC filings[2] - The presentation includes non-GAAP financial measures used by management to evaluate performance, but these should not be considered superior to GAAP measures[3, 5]

Transaction Overview - Western Union will acquire International Money Express for $1600 per share in cash[16] - The transaction is expected to close in mid-2026, pending regulatory approvals and closing conditions[18] - The acquisition is expected to yield $30 million in annual run-rate cost synergies within 24 months[16] - The transaction is expected to be immediately EPS-accretive[17] Strategic Benefits - The acquisition increases scale in high-growth LACA geographies through complementary agent networks[17] - It expands and stabilizes Western Union's U S retail footprint, enhancing resilience and improving customer access across the Americas[17] - The combined company is projected to have approximately 70000 send locations[25] - The combined company is projected to have approximately 21 million customers[25] - The combined company is projected to have approximately $2100 million in revenue[25] Financial Impact - The transaction is expected to drive an incremental $010 of Adjusted EPS in the first full year[31] - The acquisition strengthens long-term Free Cash Conversion[35]

August 11, 2025 Second Quarter 2025 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1 Agenda | 1 | Opening Remarks | | --- | --- | | 2 | Q2 2025 Highlights & Recent Accomplishments | | 3 | Our Pipeline | | 4 | Capitalizing on Market Leadership | | 5 | CARVYKTI® Performance Overview | | 6 | Financial Performance | | 7 | Q&A | 2 This presentation is for investor relations purposes only - Not for product promotional purposes ...

Financial Performance - Q2 2025 revenue was $20.5 million, compared to $23.1 million in Q2 2024[6] - Gross margin in Q2 2025 was 56.4%, compared to 57.2% in Q2 2024[6] - Adjusted EBITDA for Q2 2025 was $1.5 million, compared to $1.3 million in Q2 2024[6] - Q3 2025 revenue is projected to be in the range of $19 million to $21 million[16] - Q3 2025 gross margin is projected to be in the range of 56% to 58%[16] Regional Performance - APAC region experienced a 25.4% year-over-year decrease in Q2 2025, but with a 1.1% increase from F/X[7] - EMEA region was relatively flat, with a 0.3% year-over-year decrease in Q2 2025, but with a 5.0% increase from F/X[7] - US Pre-Clinical declined 11.7% year-over-year in Q2 2025[7] Strategic Focus - The company is prioritizing stabilizing the core business and restructuring the balance sheet to build sustainable sales and profitability[19] - The company is positioning the business for renewed growth and margin expansion in 2026 and beyond[19] - The company is focused on accelerating product adoption by leveraging a strong and innovative pipeline[19]

Company Overview - NIU was founded in 2014[3] - The company has 4,304 stores in China[3] - NIU products are sold in 53 countries[3,29] - The company has sold 5.7 million scooters globally[3] Sales Performance (Q2 2025) - China sales volume reached 319,000 units, a 54% year-over-year increase[41] - Overseas sales volume reached 33,000 units, a 36% year-over-year decrease[41] - Total revenue was RMB 1,256 million, a 34% year-over-year increase[41] Financial Metrics (Q2 2025) - Gross margin was 20.1% of revenues[45] - Adjusted operating expenses were 17.0% of revenues[45] - Net margin was -27.2%[50] - Adjusted net margin was -2.1%[53] Balance Sheet (June 30, 2025) - Cash, restricted cash, deposits & short-term investment totaled RMB 1,441 million[48] - Total assets amounted to RMB 3,094 million[48] - Total liabilities amounted to RMB 2,190 million[48]

Financial Performance & Strategy - Diversified Energy's total stakeholder returns since its 2017 IPO include approximately $2 billion in shareholder returns and debt principal payments[9] - The company completed approximately $2 billion in acquisitions recently[10] - The company made debt principal payments of $130 million[10] - The company's share repurchases are valued at approximately $43 million[10] - Dividend distributions are approximately $62 million[10] - The company's second quarter 2025 adjusted EBITDA was a record $280 million[23] - The company generated $88 million of adjusted free cash flow in the second quarter of 2025[23] Operational Highlights & Future Outlook - Total proved reserves as of July 1, 2025, were 5.98 Bcfe, a 65% increase compared to year-end 2024[11] - The company's second quarter 2025 average production was 1,149 MMcfe/d[24] - The company anticipates approximately $60 million in annualized synergies[61] - The company's 2025 guidance for adjusted EBITDA is between $825 million and $875 million[61]

August 11, 2025 Second Quarter 2025 Financial Results & Business Update On Today's Call • Welcome Brendan Strong, SVP, Investor Relations and Corporate Communications • Overview Richard Paulson, President and Chief Executive Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights Sohanya Cheng, Chief Commercial Officer and Head of Business Development ©2025 KARYOPHARM THERAPEUTICS INC. 2 • Financial Results and Guidance Lori Macomber, Chief Financial ...

Q2'25 Financial Highlights - Revenue reached $2.4 billion, a 14% increase LFL(Like-for-like) [10] - Adjusted EBITDA was $137 million, up 12% LFL [10] - Adjusted Diluted EPS stood at $0.55, reflecting a 9% increase [10] Segment Performance - Fresh Fruit revenue increased by 14.2% to $972 million [32, 35], with Adjusted EBITDA up by 3% to $72.7 million [32, 35] - Diversified Fresh Produce – EMEA saw a revenue increase of 16.5% to $1.101 billion [37, 40], with Adjusted EBITDA up 14.7% to $49 million [37, 40] - Diversified Fresh Produce – Americas & ROW experienced an 8.5% increase in revenue to $386 million [42, 45], and Adjusted EBITDA increased by 27% to $15.4 million [42, 45] Capital Allocation and Debt - Cash CAPEX for continuing operations was $(19.4) million in Q2'25 and $(72.2) million in H1'25 [46] - Free Cash Flow from continuing operations was $(1.0) million in Q2'25 and $(132.6) million in H1'25 [46] - Net Debt stood at $(788.8) million with a Net Leverage of 2.0x as of June 30, 2025 [47] FY'25 Outlook - The company anticipates Adjusted EBITDA for continuing operations to be approximately $380 - $390 million [51] - Maintenance CAPEX for continuing operations is projected to be around $100 million [51] - Interest expense is expected to be approximately $67 million [51]

Business Highlights - Roivant completed a $1.5 billion share repurchase program in June 2025, repurchasing approximately 149 million shares at an average price of $10.09, reducing the share count by over 15%[23] - The company expanded its pipeline by initiating 6 potentially registrational studies and 3 proof-of-concept (POC) studies[23] - Roivant increased shareholder exposure to clinical and litigation catalysts over the next 36 months[23] Brepocitinib Program - Topline data from the Phase 3 VALOR study of brepocitinib in dermatomyositis (DM) is expected in the second half of 2025[20, 27] - The VALOR study enrolled 241 adults with active DM, with 38% from the US, 32% from the EU, and 30% from the rest of the world[35] - Approximately 40% of subjects taking oral corticosteroids (OCS) at baseline in the VALOR study were able to eliminate OCS entirely by the end of the study[45] LNP Litigation - Summary judgment phase is ongoing in the US Moderna case, with a jury trial scheduled for March 2026[18, 27, 52] - Ongoing progress is expected in the Pfizer/BioNTech case following the Markman hearing, with a decision potentially in 2025[18, 27, 52] Financial Update - Research and development (R&D) expense was $153 million, with an adjusted R&D expense of $141 million (non-GAAP)[58] - General and administrative (G&A) expense was $134 million, with an adjusted G&A expense of $63 million (non-GAAP)[58] - Roivant had $4.5 billion in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2025[58]

Financial Performance - Plus500 announced shareholder returns of $365 million in YTD 2025[8] - Total shareholder returns since IPO in 2013 reached $2.7 billion[10] - H1 2025 revenue increased by 4% to $415.1 million compared to $398.2 million in H1 2024[107, 114] - EBITDA for H1 2025 grew by 1% to $185.1 million from $183.9 million in H1 2024[107, 114] - The company maintains a strong balance sheet with cash balances of over $0.9 billion and no debt[49, 72] Customer Metrics - Average deposit per active customer increased by 105% to approximately $17,250 in H1 2025[14, 107] - Active customers increased by 2% to 179,931 in H1 2025[52, 107] - 89% of OTC revenue in H1 2025 was generated through mobile and tablet offerings[14, 99] - 66% of OTC revenue was derived from customers trading with Plus500 for over three years[14] Strategic Growth - Non-OTC revenue is anticipated to be more than $100 million in FY 2025[61] - Customer segregated funds in the US futures market reached approximately $850 million as of June 30, 2025[67]